----

| Delaware(State of incorporation) | 94-3018487(I.R.S. Employer Identification No.) |
|----------------------------------|------------------------------------------------|

----

----

| Part III |                                                                                           |   |
|----------|------------------------------------------------------------------------------------------------|--------|
|     |                                                                                           |   |
| ITEM 10. | Directors, Executive Officers and Corporate Governance                                         | 4      |
| ITEM 11. | Executive Compensation                                                                         | 9      |
| ITEM 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 19     |
| ITEM 13. | Certain Relationships and Related Transactions, and Director Independence                      | 21     |
| ITEM 14. | Principal Accounting Fees and Services                                                         | 21     |
|     |                                                                                           |   |
| Part IV  |                                                                                           |   |
|     |                                                                                           |   |
| ITEM 15. | Exhibits and Financial Statement Schedules                                                     | 22     |

----

| ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE. |
|----------|---------------------------------------------------------|

| Nominee                  | Age    |
|--------------------------|--------|
| Craig W. Moore           | 70     |
|                     |   |
| Patrick J. McEnany       | 67     |
|                     |   |
| Mahendra S. Rao, MD, PhD | 53     |
|                     |   |
| Robin C. Stracey         | 56     |
|                     |   |
| Matthew T. Plavan        | 50     |
|                     |   |
| Kenneth L. Harris        | 50     |

| Craig W. Moore, Chairman | Director since 2009 |
|--------------------------|---------------------|

| Patrick J. McEnany | Director rejoined in 1997 |
|--------------------|---------------------------|

| Mahendra S. Rao, MD, PhD | Director rejoined in 2014 |
|--------------------------|---------------------------|

----

| Robin C. Stracey | Director since 2011 |
|------------------|---------------------|

| Matthew T. Plavan | Director since 2012 |
|-------------------|---------------------|

| Kenneth L. Harris | Director since 2014 |
|-------------------|---------------------|

----

| Name                  | Position                                        | Age |
|-----------------------|-------------------------------------------------|-----|
| Mr. Matthew Plavan    | Chief Executive Officer                         | 50  |
| Mr. Dan Bessey        | Chief Financial Officer                         | 49  |
| Mr. Ken Harris        | President, appointed on February 18, 2014       | 50  |
| Mr. Mitchel Sivilotti | Chief Biologist, appointed on February 18, 2014 | 37  |
| Mr. Kenneth Pappa     | VP, Manufacturing & IT                      | 53  |

----

|  | - | Majority of the members of the Board should be independent directors; |
|--|---|-----------------------------------------------------------------------|

|  | - | Formalization of the ability of each committee to retain independent advisors; |
|--|---|--------------------------------------------------------------------------------|

|  | - | Performance of an annual assessment of the Board’s performance by the Governance and Nominating Committee; |
|--|---|------------------------------------------------------------------------------------------------------------------|

|  | - | Directors will have open access to the Company’s management; and |
|--|---|------------------------------------------------------------------------|

|  | - | Independent directors may meet in executive session prior to or after each regularly scheduled Board meeting without management present. |
|--|---|------------------------------------------------------------------------------------------------------------------------------------------|

----

----

| ITEM 11. | EXECUTIVE COMPENSATION. |
|----------|-------------------------|

|   | • | base salary |
|--------|---------|-------------|

|   | • | short-term incentive (“STI”) |
|--------|---------|------------------------------------------|

|   | • | long-term incentive ("LTI") |
|--------|---------|-----------------------------|

----

----

----

| Named Executive Officer                           | Percentage of Base Salary subject to STI |
|---------------------------------------------------|------------------------------------------|
| Matthew Plavan, Chief Executive Officer           | 60%                                      |
| Kenneth Harris, President                         | 45%                                      |
| Dan Bessey, Chief Financial Officer               | 45%                                      |
| Mitchel Sivilotti, Chief Biologist                | 45%                                      |
| Ken Pappa, Vice President of Manufacturing and IT | 35%                                      |

----

| Named Executive Officer | Options |
|-------------------------|---------|
| Matthew Plavan          | 400,000 |
| Kenneth Harris          | 160,000 |
| Dan T. Bessey           | 160,000 |
| Mitchel Sivilotti       | 80,000  |
| Ken Pappa               | 80,000  |

----

| SUMMARY COMPENSATION TABLE  |   |
|-----------------------------|--------|
|                             |   |
| Name and Principal Position | Year   |   | Salary($) |   |   | Bonus($) |   |   | Stock Awards($)(1) |   |   | Option Awards($)(1) |   |   | All Other Compensation($) |   |   | Total($) |   |
| Matthew Plavan              | 2014   |   |   | 349,000 |   |   |   | 100,000 | (2)  |   |   | 458,000 |   |   |   | 122,000 |   |   |   | -- |   |   |   | 1,029,000 |   |
| Chief Executive Officer     | 2013   |   |   | 315,000 |   |   |   | -- |   |   |   | -- |   |   |   | 88,000 |   |   |   | -- |   |   |   | 403,000 |   |
|                             | 2012   |   |   | 315,000 |   |   |   | -- |   |   |   | 149,000 |   |   |   | -- |   |   |   | -- |   |   |   | 464,000 |   |
| Dan Bessey                  | 2014   |   |   | 259,000 |   |   |   | 50,000 | (2)  |   |   | 147,000 |   |   |   | 41,000 |   |   |   | -- |   |   |   | 497,000 |   |
| Chief Financial Officer     | 2013   |   |   | 61,000 |   |   |   | -- |   |   |   | 46,000 |   |   |   | 22,000 |   |   |   | -- |   |   |   | 129,000 |   |
| Ken Harris                  | 2014   |   |   | 96,000 |   |   |   | 40,000 | (4)  |   |   | 109,000 |   |   |   | 121,000 |   |   |   | 4,000 | (5)  |   |   | 370,000 |   |
| President(3)                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Mitchel Sivilotti           | 2014   |   |   | 74,000 |   |   |   | 40,000 | (4)  |   |   | 109,000 |   |   |   | 121,000 |   |   |   | 4,000 | (5)  |   |   | 348,000 |   |
| Chief Biologist(6)          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Ken Pappa                   | 2014   |   |   | 247,000 |   |   |   | 10,000 | (2)  |   |   | 82,000 |   |   |   | 23,000 |   |   |   | -- |   |   |   | 362,000 |   |
| V.P., Manufacturing         | 2013   |   |   | 245,000 |   |   |   | 25,000 | (7)  |   |   | -- |   |   |   | -- |   |   |   | -- |   |   |   | 270,000 |   |
| and IT                      | 2012   |   |   | 239,000 |   |   |   | -- |   |   |   | 99,000 |   |   |   | -- |   |   |   | -- |   |   |   | 338,000 |   |
| Hal Baker                   | 2014   |   |   | 211,000 |   |   |   | 75,000 | (8)  |   |   | 82,000 |   |   |   | 23,000 |   |   |   | 160,000 | (9)  |   |   | 551,000 |   |
| Former V.P., Commercial     | 2013   |   |   | 263,000 |   |   |   | 99,000 | (8)  |   |   | -- |   |   |   | -- |   |   |   | 8,000 | (10)  |   |   | 370,000 |   |
| Operations & Marketing  | 2012   |   |   | 262,000 |   |   |   | 85,000 | (8)  |   |   | 99,000 |   |   |   | -- |   |   |   | 9,000 | (10)  |   |   | 455,000 |   |

| (1) | The amounts reported are the aggregate grant date fair value of the awards computed in accordance with Financial Accounting Standards Board’s Codification topic 718. See Note 1 of notes to Financial Statements set forth in our Annual Report on Form 10-K for fiscal 2014 for the assumptions used in determining such amounts. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Represents a bonus for contribution to the achievement of the corporate milestones including the acquisition of TotipotentRX merger and formation of the combined company, Cesca Therapeutics, and the capital market financing. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | Mr. Harris became the President upon the merger with TotipotentRX on February 18, 2014. |
|-----|-----------------------------------------------------------------------------------------|

| (4) | Represents a relocation payment. |
|-----|----------------------------------|

| (5) | Represents payments for an auto allowance. |
|-----|--------------------------------------------|

| (6) | Mr. Sivilotti became the Chief Biologist upon the merger with TotipotentRX on February 18, 2014. |
|-----|--------------------------------------------------------------------------------------------------|

| (7) | Represents a bonus for the completion of the sale of the CryoSeal product line. |
|-----|---------------------------------------------------------------------------------|

| (8) | Represents commission payments as Vice President in charge of sales. |
|-----|----------------------------------------------------------------------|

| (9) | Includes $23,000 pay-out of accrued vacation balance and $131,000 severance upon termination of employment on April 10, 2014. The severance will be paid out over six months. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (10) | Includes $8,000 in payments for an auto allowance. |
|------|----------------------------------------------------|

----

|            |   | Option Awards                                                       |   | Stock Awards |                                                                  |
|-----------------|--------|---------------------------------------------------------------------|--------|--------------|-----------------------------------------------------------------------|
| Name            |   | Number of Securities Underlying Unexercised Options (#) Exercisable |   |         | Number of Securities Underlying Unexercised Options (#) Unexercisable |   |   | Option Exercise Price ($) |   | Option Expiration Date |   | Number of Shares or Units of Stock That Have Not Vested (#) |   |   | Market Value of Shares or Units of Stock That Have Not Vested ($) |   |
| Matthew Plavan  |   |                                                                | 50,000 |         |                                                                  |   | -- |   |   |   | 2.32 |   | 6/10/15 |   |  |   |   |  |   |
|            |   |                                                                | 37,500 |         |                                                                  |   | 12,500 | (1)  |   |   | 2.88 |   | 2/15/16 |   |  |   |   |  |   |
|            |   |                                                                | 54,167 |         |                                                                  |   | 108,333 | (2)  |   |   | 0.93 |   | 7/29/16 |   |  |   |   |  |   |
|            |   |                                                                | --     |         |                                                                  |   | 100,000 | (3)  |   |   | 2.18 |   | 3/3/18 |   |  |   |   |  |   |
|            |   |                                                                |   |         |                                                                  |   |   |   |   |   |   |   |   |   |   | 25,000 | (4)  |   |   | 35,000 |   |
|            |   |                                                                |   |         |                                                                  |   |   |   |   |   |   |   |   |   |   | 210,000 | (3)  |   |   | 292,000 |   |
| Dan Bessey      |   |                                                                | 16,667 |         |                                                                  |   | 33,333 | (5)  |   |   | 0.91 |   | 3/26/17 |   |   |   |   |   |   |   |   |
|            |   |                                                                | --     |         |                                                                  |   | 33,585 | (3)  |   |   | 2.18 |   | 3/3/18 |   |   |   |   |   |   |   |   |
|            |   |                                                                |   |         |                                                                  |   |   |   |   |   |   |   |   |   |   | 33,333 | (5)  |   |   | 46,000 |   |
|            |   |                                                                |   |         |                                                                  |   |   |   |   |   |   |   |   |   |   | 67,500 | (3)  |   |   | 94,000 |   |
| Ken Harris      |   |                                                                | --     |         |                                                                  |   | 100,000 | (6)  |   |   | 2.17 |   | 2/18/20 |   |   |   |   |   |   |   |   |
|            |   |                                                                |   |         |                                                                  |   |   |   |   |   |   |   |   |   |   | 50,000 | (6)  |   |   | 70,000 |   |
| Mitch Sivilotti |   |                                                                | --     |         |                                                                  |   | 100,000 | (6)  |   |   | 2.17 |   | 2/18/20 |   |   |   |   |   |   |   |   |
|            |   |                                                                |   |         |                                                                  |   |   |   |   |   |   |   |   |   |   | 50,000 | (6)  |   |   | 70,000 |   |
| Ken Pappa       |   |                                                                | 18,750 |         |                                                                  |   | -- |   |   |   | 2.32 |   | 6/10/15 |   |   |   |   |   |   |   |   |
|            |   |                                                                | 14,063 |         |                                                                  |   | 4,687 | (1)  |   |   | 2.88 |   | 2/15/16 |   |   |   |   |   |   |   |   |
|            |   |                                                                | --     |         |                                                                  |   | 18,700 | (3)  |   |   | 2.18 |   | 3/3/18 |   |   |   |   |   |   |   |   |
|            |   |                                                                |   |         |                                                                  |   |   |   |   |   |   |   |   |   |   | 16,667 | (4)  |   |   | 23,000 |   |
|            |   |                                                                |   |         |                                                                  |   |   |   |   |   |   |   |   |   |   | 37,500 | (3)  |   |   | 52,000 |   |
| Hal Baker       |   |                                                                | 28,125 |         |                                                                  |   | -- |   |   |   | 2.88 |   | 7/9/14 |   |   |   |   |   |   |   |   |
|            |   |                                                                | 28,125 |         |                                                                  |   | -- |   |   |   | 2.32 |   | 7/9/14 |   |   |   |   |   |   |   |   |

| (1) | Vests on February 15, 2015. |
|-----|-----------------------------|

| (2) | Vests on July 29, 2015. |
|-----|-------------------------|

| (3) | One-third vests on March 3, 2015, 2016 and 2017. |
|-----|--------------------------------------------------|

| (4) | Vests on July 29, 2014. |
|-----|-------------------------|

| (5) | One-half vests on March 26, 2015 and 2016. |
|-----|--------------------------------------------|

| (6) | One-third vests on February 18, 2015, 2016 and 2017. |
|-----|------------------------------------------------------|

----

|         |   | Termination Without Cause orResignation for Good Reason |    |      | Termination following a Change of Control(1)(2)                                |   |
|--------------|--------|---------------------------------------------------------|---------|-----------|--------------------------------------------------------------------------------|--------|
| Name         |   | Salary($)                                               |    |      | Estimated Value of Accelerated Stock Options and Restricted Stock Awards(3)($) |   |   | Health Benefits($) |   |   | Total($) |   |   | Salary($) |   |   | Incentive Compensation($) |   |   | Estimated Value of Accelerated Stock Options and Restricted Stock Awards(3)($) |   |   | Health Benefits/ Office Stipend($) |   |   | Total($) |   |
| M. Plavan    |   |                                                    | 425,000 | (4)  |                                                                           |   | 139,000 |   |   |   | -- |   |   |   | 564,000 |   |   |   | 637,000 |   |   |   | 383,000 |   |   |   | 444,000 |   |   |   | 42,000 |   |   |   | 1,506,000 |   |
| D. Bessey    |   |                                                    | 210,000 | (4)  |                                                                           |   | -- |   |   |   | -- |   |   |   | 210,000 |   |   |   | 280,000 |   |   |   | 126,000 |   |   |   | 170,000 |   |   |   | 28,000 |   |   |   | 604,000 |   |
| K. Harris    |   |                                                    | 420,000 | (5)(6)    |                                                                           |   | 23,000 |   |   |   | -- |   |   |   | 443,000 |   |   |   | 420,000 | (6)  |   |   | -- |   |   |   | 95,000 |   |   |   | 111,000 |   |   |   | 626,000 |   |
| M. Sivilotti |   |                                                    | 323,000 | (6)  |                                                                           |   | 23,000 |   |   |   | -- |   |   |   | 346,000 |   |   |   | 323,000 | (6)  |   |   | -- |   |   |   | 95,000 |   |   |   | 111,000 |   |   |   | 529,000 |   |
| K. Pappa     |   |                                                    | 125,000 |      |                                                                           |   | -- |   |   |   | 14,000 |   |   |   | 139,000 |   |   |   | 250,000 |   |   |   | -- |   |   |   |   |   |   |   | -- |   |   |   | 250,000 |   |

| (1) | If we terminate Mr. Plavan or Mr. Bessey’s employment without cause, or if the executive resigned for good reason as defined in his executive employment agreement, in either case within three (3) months prior to a Change of Control or within one (1) year following a Change of Control, then he would have been entitled to receive the amounts listed as shown in the table. The salary and incentive compensation components are payable in a lump-sum payment. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | If we terminate Mr. Harris or Mr. Sivilotti’s employment without cause, or if the executive resigned for good reason as defined in his executive employment agreement, in either case with one (1) year following a Change of Control, then he would have been entitled to receive the amounts listed as shown in the table. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | For purposes of this calculation, we used the closing price of our Common Stock on June 30, 2014 which was $1.39. The estimated value of accelerated vesting for outstanding stock options is zero for all options in which the exercise price exceeded the closing price of our Common Stock as of June 30, 2014. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4) | Payable in biweekly installments. |
|-----|-----------------------------------|

|  | (5) | If Mr. Harris’ resigns for either (i) the Board fails to nominate Executive for re-election as a director of Employer at any shareholder meeting held to elect directors that occurs within three years after February 18, 2014, or (ii) Mr. Harris is removed as a director of Employer by the Board of Directors before February 18, 2017, he will receive an additional $140,000. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (6) | Payable in biweekly installments over 18 months. |
|-----|--------------------------------------------------|

| a) | the Company issues securities equal to 50% or more of the Company’s issued and outstanding voting securities, determined as a single class; |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------|

| b) | the Company issues securities equal to 50% or more of the issued and outstanding common stock of the Company in connection with a merger, consolidation or other business combination; |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| c) | the Company is acquired in a merger or other business combination transaction in which the Company is not the surviving company; or |
|----|-------------------------------------------------------------------------------------------------------------------------------------|

| d) | all or substantially all of the Company’s assets are sold or transferred. |
|----|---------------------------------------------------------------------------------|

----

|   | a) | the Company issues securities equal to fifty percent (50%) or more of the Company’s issued and outstanding voting securities, determined as a single class, to any individual, firm, partnership or other entity, including a “group” within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934; |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b) | the Company issues securities equal to fifty percent (50%) or more of the issued and outstanding common stock of the Company in connection with a merger, consolidation or other business combination; |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c) | the Company is acquired in a merger or other business combination transaction in which the Company is not the surviving company; or |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------|

|   | d) | all or substantially all of the Company’s assets are sold or transferred to a third party. |
|--------|----|--------------------------------------------------------------------------------------------------|

|   | a) | the Company issues securities equal to forty percent (40%) or more of the Company’s issued and outstanding voting securities, determined as a single class, to any individual, firm, partnership or other entity, including a “group” within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934; |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b) | the Company issues securities equal to forty percent (40%) or more of the issued and outstanding common stock of the Company in connection with a merger, consolidation or other business combination; |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c) | the Company is acquired in a merger or other business combination transaction in which the Company is not the surviving company; or |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------|

|   | d) | all or substantially all of the Company’s assets are sold or transferred to a third party. |
|--------|----|--------------------------------------------------------------------------------------------------|

----

| Name                   |   | Fees Earned or Paid in Cash(1)($) |   |   | Option Awards(2)(3)($) |   |   | Total($)  |   |
|------------------------|--------|-----------------------------------|--------|--------|------------------------|--------|--------|-----------|--------|
| Mr. Craig W. Moore     |   |                              | 91,000 |   |                   |   | 10,000 | (4)  |   |   | 101,000 |   |
| Mr. Patrick J. McEnany |   |                              | 68,000 |   |                   |   | 10,000 | (4)  |   |   | 78,000 |   |
| Dr. Mahendra S. Rao    |   |                              | 9,000  |   |                   |   | 31,000 | (5)  |   |   | 40,000 |   |
| Mr. Robin C. Stracey   |   |                              | 70,000 |   |                   |   | 10,000 | (4)  |   |   | 80,000 |   |

| (1) | Prior to the beginning of the fiscal year Mr. Moore and Mr. Stracey elected to receive common stock in lieu of cash for a portion of their Board of Directors fees, which fees are paid in quarterly installments. The grant date fair value of the stock received computed in accordance with ASC718 was $32,000 and $36,000 for Mr. Moore and Mr. Stracey, respectively. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | The amounts reported are the aggregate grant date fair value of the awards computed in accordance with Financial Accounting Standards Board’s Codification topic 718. See Note 1 of notes to Financial Statements set forth in our Annual Report on Form 10-K for fiscal 2014 for the assumptions used in determining such amounts for option awards.The following table sets forth the aggregate number of option awards held by each non-employee director as of June 30, 2014. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | $10,000 reflects the grant date fair value of the annual option awarded to existing directors on the first business day of the fiscal year. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------|

| (4) | $31,000 reflects the grant date fair value of the stock option grant of 25,000 shares due to Dr. Rao upon joining the Board. |
|-----|------------------------------------------------------------------------------------------------------------------------------|

| Name                   | Aggregate Number ofOption Awards |
|------------------------|----------------------------------|
| Mr. Craig W. Moore     | 70,000                           |
| Mr. Patrick J. McEnany | 101,500                          |
| Dr. Mahendra S. Rao    | 25,000                           |
| Mr. Robin C. Stracey   | 40,000                           |

----

| ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS. |
|----------|-------------------------------------------------------------------------------------------------|

| Plan Category                                              |   | Number of securities to be issued upon exercise of outstanding options and restricted stock(a) |      |   | Weighted-average exercise price of outstanding options(b) |   |   | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)(1))(c) |   |
|------------------------------------------------------------|--------|------------------------------------------------------------------------------------------------|-----------|--------|-----------------------------------------------------------|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| Equity compensation plans approved by security holders     |   |                                                                                           | 2,056,834 |   |                                                      | $      | 2.08   |                                                                                                                                              |   |   | 649,381 |   |
| Equity compensation plans not approved by security holders |   |                                                                                           | --        |   |                                                      |   |   |                                                                                                                                              |   |   | -- |   |
| Total                                                      |   |                                                                                           | 2,056,834 |   |                                                      |   |   |                                                                                                                                              |   |   | 649,381 |   |

| (1) | Under the Company’s 2006 Equity Incentive Plan, the number of shares of common stock equal to six percent (6%) of the number of outstanding shares of the Company are authorized to be used. Under this provision, the number of shares available to grant for awards will increase at the beginning of each fiscal year if options were granted or additional shares of common stock were issued in the preceding fiscal year. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Name and Address of Beneficial Owner            |   | Amount and Nature of Beneficial Ownership(1) |      |      | Percent of Class |   |
|-------------------------------------------------|--------|----------------------------------------------|-----------|-----------|------------------|--------|
| Craig Moore                                     |   |                                         | 139,254   | (2)  |             |   | * | % |
|                                            |   |                                         |      |      |             |   |   |   |
| Patrick McEnany                                 |   |                                         | 121,207   | (3)  |             |   | * | % |
|                                            |   |                                         |      |      |             |   |   |   |
| Mahendra Rao MD, PhD.                           |   |                                         | 14,584    | (4)  |             |   | * | %  |
|                                            |   |                                         |      |      |             |   |   |   |
| Robin Stracey                                   |   |                                         | 94,572    | (5)  |             |   | * | % |
|                                            |   |                                         |      |      |             |   |   |   |
| Matthew Plavan                                  |   |                                         | 271,935   | (6)  |             |   | * | % |
|                                            |   |                                         |      |      |             |   |   |   |
| Dan Bessey                                      |   |                                         | 33,334    | (7)  |             |   | * | % |
|                                            |   |                                         |      |      |             |   |   |   |
| Ken Harris                                      |   |                                         | 4,547,102 |      |             |   | 11.3 | % |
|                                            |   |                                         |      |      |             |   |   |   |
| Mitch Sivilotti                                 |   |                                         | 4,617,231 |      |             |   | 11.5 | % |
|                                            |   |                                         |      |      |             |   |   |   |
| Ken Pappa                                       |   |                                         | 81,889    | (8)  |             |   | * | % |
|                                            |   |                                         |      |      |             |   |   |   |
| Officers & Directors as a Group (9 persons) |   |                                         | 9,921,108 |      |             |   | 24.4 | % |

| * | Less than 1%. |
|---|---------------|

| (1) | “Beneficial Ownership” is defined pursuant to Rule 13d-3 of the Exchange Act, and generally means any person who directly or indirectly has or shares voting or investment power with respect to a security. A person shall be deemed to be the beneficial owner of a security if that person has the right to acquire beneficial ownership of the security within 60 days, including, but not limited to, any right to acquire the security through the exercise of any option or warrant or through the conversion of a security. Any securities not outstanding that are subject to options or warrants shall be deemed to be outstanding for the purpose of computing the percentage of outstanding securities of the class owned by that person, but shall not be deemed to be outstanding for the purpose of computing the percentage of the class owned by any other person. Some of the information with respect to beneficial ownership has been furnished to us by each director or officer, as the case may be. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Includes 70,087 common shares and 69,167 shares issuable upon the exercise of options. |
|-----|----------------------------------------------------------------------------------------|

| (3) | Includes 26,832 common shares and 94,167 shares issuable upon the exercise of options. Also includes 208 shares owned by McEnany Holding, Inc. Mr. McEnany is the sole shareholder of McEnany Holding, Inc. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4) | Represents common shares issuable upon the exercise of options. |
|-----|-----------------------------------------------------------------|

| (5) | Includes 50,405 common shares and 44,167 common shares issuable upon the exercise of options. |
|-----|-----------------------------------------------------------------------------------------------|

| (6) | Includes 76,102 common shares and 195,833 shares issuable upon the exercise of options. |
|-----|-----------------------------------------------------------------------------------------|

| (7) | Includes 16,667 common shares and 16,667 shares issuable upon the exercise of options. |
|-----|----------------------------------------------------------------------------------------|

| (8) | Includes 49,076 common shares and 32,813 common shares issuable upon the exercise of options. |
|-----|-----------------------------------------------------------------------------------------------|

----

| ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE. |
|----------|----------------------------------------------------------------------------|

| ITEM 14. | PRINCIPAL ACCOUNTING FEES AND SERVICES. |
|----------|-----------------------------------------|

| Fee Category          |   | Fiscal 2014 |      |   | Fiscal 2013 |   |
|-----------------------|--------|-------------|-----------|--------|-------------|--------|
| Audit Fees(1)         |   | $           | 888,000   |   |        | $      | 410,000 |   |
| Audit-Related Fees(2) |   |        | 532,000   |   |        |   | 94,000 |   |
| Tax Fees(3)           |   |        | 22,000    |   |        |   | 21,000 |   |
| All Other Fees(4)     |   |        | --        |   |        |   | -- |   |
| Total Fees            |   | $           | 1,442,000 |   |        | $      | 525,000 |   |

| (1) | The audit fees for fiscal 2014 and fiscal 2013 consisted of fees for the audit of our financial statements, the review of the interim financial statements included in our quarterly reports on Form 10-Q, and other professional services provided in connection with statutory and regulatory filings or engagements and capital market financings. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Includes fees billed for due diligence services regarding the proposed merger with TotipotentRX. |
|-----|--------------------------------------------------------------------------------------------------|

| (3) | Tax fees consist of fees for tax compliance, which relate to the preparation of federal and state tax returns. |
|-----|----------------------------------------------------------------------------------------------------------------|

| (4) | All other fees consist of fees for other permissible work performed by Ernst & Young LLP that does not meet with the above category descriptions. There were no fees for other services by Ernst & Young LLP for the fiscal years ended June 30, 2014 and 2013. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ITEM 15. | EXHIBITS AND FINANCIAL STATEMENT SCHEDULES |
|----------|--------------------------------------------|

| (b) | Exhibits |
|-----|----------|

| Exhibit No. | Document Description                                                                                                                   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------|
| 31.1        | Certification by the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                             |
| 31.2        | Certification by the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                             |
| 32     | Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002 |

----

|                    |   | Cesca Therapeutics Inc. |
|-------------------------|--------|-------------------------|
|                    |   |                    |
| Dated: October 28, 2014 | By:/s/ | Dan T. Bessey           |
|                    |   | Chief Financial Officer |

----